Go Pro
NASDAQ:ZYXI

Zynex (ZYXI) Stock Price, News & Analysis

Zynex logo
$0.12 0.00 (0.00%)
As of 07/31/2026

About Zynex Stock (NASDAQ:ZYXI)

Advanced

Key Stats

Today's Range
$0.13
$0.13
50-Day Range
$0.13
$0.13
52-Week Range
$0.12
$2.82
Volume
N/A
Average Volume
2.32 million shs
Market Capitalization
$3.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Zynex, Inc. is a medical device company engaged in the design, development, manufacture and sale of non-invasive therapeutic and patient monitoring equipment in the United States. Headquartered in Englewood, Colorado, the company focuses on delivering FDA-cleared solutions aimed at pain management, neurological rehabilitation and remote patient monitoring. Zynex’s portfolio is structured to address the needs of healthcare providers, outpatient clinics and patients receiving care in their homes.

The company’s core product offerings include electrotherapy devices—such as transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical stimulation (NMES) systems—designed to alleviate pain and assist in muscle recovery. Zynex also markets a range of soft goods, including bracing and support products, as well as disposable electrodes and accessories. In addition, the firm provides remote monitoring technologies that capture vital signs data, enabling clinicians to track patient health metrics outside of traditional care settings.

Zynex distributes its products primarily through a direct-to-provider sales model, supported by a field organization that spans multiple U.S. regions. The company works closely with hospitals, rehabilitation centers, home health agencies and durable medical equipment (DME) providers to integrate its therapies and monitoring systems into patient care protocols. By offering rental and purchase options, Zynex caters to a variety of reimbursement environments and patient needs.

Founded in 1996, Zynex has grown both organically and through selective acquisitions to expand its product lines and geographic reach. The company is led by Robert B. Rempel, who serves as President, Chief Executive Officer and Chairman of the Board, bringing decades of experience in healthcare innovation and corporate leadership. With a commitment to research, regulatory compliance and customer education, Zynex continues to pursue advances that enhance patient outcomes and support the evolving demands of modern healthcare delivery.

AI Generated. May Contain Errors.

Receive ZYXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZYXI Stock News Headlines

Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

ZYXI Stock Analysis - Frequently Asked Questions

Zynex's stock was trading at $0.1260 at the beginning of the year. Since then, ZYXI stock has decreased by 0.8% and is now trading at $0.1250.

Zynex Inc. (NASDAQ:ZYXI) announced its earnings results on Monday, April, 28th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.09. The firm earned $26.58 million during the quarter, compared to analyst estimates of $30.83 million. Zynex had a negative trailing twelve-month return on equity of 804.30% and a negative net margin of 68.35%.
Read the conference call transcript
.

Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynex investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
4/28/2025
Today
8/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:ZYXI
CIK
846475
Fax
N/A
Employees
770
Year Founded
1996

Profitability

EPS (Trailing Twelve Months)
($2.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.63
P/E Growth
N/A
Net Income
$2.99 million
Net Margins
-68.35%
Pretax Margin
-65.57%
Return on Equity
-804.30%
Return on Assets
-36.67%

Debt

Debt-to-Equity Ratio
0.56
Current Ratio
0.47
Quick Ratio
0.32

Sales & Book Value

Annual Sales
$108.20 million
Price / Sales
0.04
Cash Flow
$0.25 per share
Price / Cash Flow
0.51
Book Value
$1.12 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
30,389,000
Free Float
15,413,000
Market Cap
$3.80 million
Optionable
Optionable
Beta
0.99

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ZYXI) was last updated on 8/1/2026 by MarketBeat.com Staff.
From Our Partners